Skip to content

Stress Management and Biomarkers of Risk in Cardiac Rehabilitation

Enhancing Standard Cardiac Rehabilitation With Stress Management Training in Patients With Heart Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00981253
Acronym
ENHANCED
Enrollment
164
Registered
2009-09-22
Start date
2009-09-30
Completion date
2016-02-29
Last updated
2018-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Keywords

Stress Management Training, Cardiac Rehabilitation, Stress, Depression

Brief summary

The purpose of this study is to assess the extent to which combining exercise and stress management training (SMT) is more effective at improving biomarkers in vulnerable cardiac patients compared to exercise-based cardiac rehabilitation alone.

Detailed description

Coronary heart disease (CHD) is the leading cause of death in the United States and in roughly half the cases its first clinical manifestations, myocardial infarction (MI) or sudden cardiac death (SCD), are fatal. There is considerable evidence that stress plays a significant and independent role in the occurrence of CHD and its complications. This evidence has provided the rationale for developing interventional strategies to reduce stress in susceptible individuals in order to modify the natural history of these clinical events. There are now promising data to suggest that stress management training (SMT) is one such approach, and that SMT can have beneficial effects on psychosocial and medical outcomes. However, many of the randomized clinical trials (RCTs) employing stress management approaches in CHD patients have had important methodological limitations and several of the larger RCTs have failed to demonstrate a benefit for SMT over usual care, raising questions about the value of SMT for patients with CHD. Reliance on hard clinical endpoints is problematic because studies require such large sample sizes that they are logistically difficult to conduct and are prohibitively expensive. The use of intermediate pathophysiologic endpoints that have been shown independently to be associated with increased risk represents a novel and exciting opportunity to examine the added value of SMT in exercise-based cardiac rehabilitation (CR) compared to CR without SMT on key biomarkers of risk in vulnerable CHD patients. This 12-week study will enroll adults with stable CHD who are eligible for CR. Participants will be randomly assigned to either standard cardiac rehabilitation or standard cardiac rehabilitation enhanced with weekly SMT. Prior to randomization, medical screening, standardized psychosocial questionnaires, mental stress testing, assessment of diet and physical activity, and exercise testing will be conducted. Additional biomarkers of risk will be assessed through measures of flow-mediated vasodilation, inflammation, platelet function, stress hormones, baroreflex, and heart rate variability. Participants assigned to CR alone will engage in supervised exercise routines 3 times per week. Participants will be encouraged to maintain consistent exercise duration and effort throughout each session. Participants assigned to CR enhanced with SMT will engage in standard exercise-based cardiac rehabilitation and also receive weekly group SMT. At the conclusion of the 12-week intervention, participants will return for repeat assessments of stress and biomarker measures. At 6 months, 12 months, and annually up to 4 years participants will be contacted for information regarding major adverse cardiovascular events, other medical events and medication use. Additionally a group of age, gender, and disease matched cardiac patients referred to CR, during the same time interval, but who elected not to participate in CR will form a non-randomized comparison group for cardiac events. Overall, 164 participants were consented for study participation at Duke University Medical Center. Of these, 151 participants were randomized to either Standard Cardiac Rehabilitation or Enhanced Cardiac Rehabilitation. Post-intervention assessments were completed on 145 participants; 151 participants were available for intention-to-treat analysis.

Interventions

BEHAVIORALSMT-enhanced Cardiac Rehabilitation

Standard exercise-based cardiac rehabilitation, three times per week, enhanced with weekly stress management training for 12 weeks.

Supervised exercise, three times per week, for 12 weeks.

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
Duke University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
35 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of Coronary Heart Disease (CHD) * Eligibility for Cardiac Rehabilitation (CR) in North Carolina * Capacity to give informed consent and follow study procedures

Exclusion criteria

* Received heart transplant * LVEF \< 30% * Labile ECG changes prior to testing * Currently using a pacemaker * Resting BP \> 200/120 mm Hg * Left main disease \> 50% * Unable to comply with assessment procedures * Unwilling or unable to be randomized to treatment groups * Primary diagnosis of the following psychiatric disorders: schizophrenia, dementia, current delirium, or other psychotic disorder * Current alcohol or substance abuse disorder * Acute suicide risk * Actively undergoing ongoing psychiatric treatment

Design outcomes

Primary

MeasureTime frameDescription
Absolute Composite Stress ScoreBaseline; 12 weeksA global stress measure (mean rank), was the primary outcome combining the following components at baseline and following treatment: Beck Depression Inventory II, Spielberger Anxiety Inventory-State, General Health Questionnaire, PROMIS Anger Questionnaire, and Perceived Stress Scale. A range from 1 to 147 was present with higher scores suggestive of better function. The change in each individual scaled score is presented in primary outcome 2.
Change From Baseline to 12 Weeks in Individual Scaled ScoresBaseline; 12 weeksBeck Depression Inventory II: 21-item scale used to measure depression. Scores range from 0 to 63, with higher scores suggesting greater depressive symptoms. State-Trait Anxiety Inventory: 20-item scale which assess levels of state anxiety. Scores range from 20 to 80 with scores ≥40 suggesting clinically significant anxiety. General Health Questionnaire:12-item measure of general distress. Scores range from 0 to 36, with higher scores indicating greater emotional distress. Patient-Reported Outcomes Measurement Information System (PROMIS) Anger: 8-item scale which assesses anger. Scores range from 8 to 40, with higher scores indicating greater anger. Perceived Stress Scale: 10-item measure of general distress and perceived ability to cope. Scores range from 0 to 40, higher scores indicate greater stress.

Secondary

MeasureTime frameDescription
Change in High-sensitivity C-Reactive ProteinBaseline; 12 weeksHigh-sensitivity C-reactive protein was quantified by ELISA. Values \>10 mg/L were truncated at 10 to account for acute inflammatory processes that may have skewed the distribution of this blood marker.
Heart Rate Variability During Controlled Breathing (HRV-DB)At 12 weeksHeart rate variability was obtained from beat-to-beat heart rate. Heart rate was assessed from R-R interval changes elicited during a 100-second controlled breathing task.
Heart Rate Variability During RestAt 12 weeksHeart rate variability was obtained from beat-to-beat heart rate. Heart rate was assessed from R-R interval changes elicited during 5 minutes of normal relaxed breathing
Baroreflex SensitivityAt 12 weeksBaroreflex sensitivity was obtained from beat-to-beat heart rate and blood pressure recorded from patients in the supine position with a Nexfin noninvasive blood pressure monitor.
Major Adverse Cardiovascular Events (MACE) - All Cause Death, MI, Cardiac Revascularization and Cardiovascular Hospitalization.Baseline through Follow-up (median, 3.2 years)Patients documented all medical encounters on an annual basis after enrollment. Medical records were reviewed, and events, categorized on the basis of American College of Cardiology/American Heart Association criteria. The following medical events were included: all-cause mortality, fatal and nonfatal myocardial infarction (MI), coronary or peripheral artery revascularization, stroke/transient ischemic attack, and unstable angina requiring hospitalization.

Countries

United States

Participant flow

Recruitment details

Overall, 164 participants were consented for study participation. Of these, 151 participants were randomized to either Standard Cardiac Rehabilitation or SMT-Enhanced Cardiac Rehabilitation. Post-intervention assessments were completed on 145 participants; 151 participants were available for intention-to-treat analysis.

Participants by arm

ArmCount
SMT-enhanced Cardiac Rehabilitation
Standard exercise-based cardiac rehabilitation with weekly stress management training for 12 weeks. SMT-enhanced Cardiac Rehabilitation: Standard exercise-based cardiac rehabilitation, three times per week, enhanced with weekly stress management training for 12 weeks.
76
Standard Cardiac Rehabilitation
Standard cardiac rehabilitation consisting of supervised exercise for 12 weeks. Standard Cardiac Rehabilitation: Supervised exercise, three times per week, for 12 weeks.
75
Total151

Baseline characteristics

CharacteristicStandard Cardiac RehabilitationTotalSMT-enhanced Cardiac Rehabilitation
Age, Continuous60.4 years
STANDARD_DEVIATION 10.6
61.0 years
STANDARD_DEVIATION 10.6
61.8 years
STANDARD_DEVIATION 10.8
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
1 Participants2 Participants1 Participants
Race (NIH/OMB)
Black or African American
23 Participants40 Participants17 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
51 Participants109 Participants58 Participants
Sex: Female, Male
Female
24 Participants55 Participants31 Participants
Sex: Female, Male
Male
51 Participants96 Participants45 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 760 / 75
serious
Total, serious adverse events
0 / 760 / 75

Outcome results

Primary

Absolute Composite Stress Score

A global stress measure (mean rank), was the primary outcome combining the following components at baseline and following treatment: Beck Depression Inventory II, Spielberger Anxiety Inventory-State, General Health Questionnaire, PROMIS Anger Questionnaire, and Perceived Stress Scale. A range from 1 to 147 was present with higher scores suggestive of better function. The change in each individual scaled score is presented in primary outcome 2.

Time frame: Baseline; 12 weeks

ArmMeasureValue (LEAST_SQUARES_MEAN)
SMT-enhanced Cardiac RehabilitationAbsolute Composite Stress Score77.6 Mean rank score
Standard Cardiac RehabilitationAbsolute Composite Stress Score67.5 Mean rank score
95% CI: [-18.7, -1.5]ANCOVA
Primary

Change From Baseline to 12 Weeks in Individual Scaled Scores

Beck Depression Inventory II: 21-item scale used to measure depression. Scores range from 0 to 63, with higher scores suggesting greater depressive symptoms. State-Trait Anxiety Inventory: 20-item scale which assess levels of state anxiety. Scores range from 20 to 80 with scores ≥40 suggesting clinically significant anxiety. General Health Questionnaire:12-item measure of general distress. Scores range from 0 to 36, with higher scores indicating greater emotional distress. Patient-Reported Outcomes Measurement Information System (PROMIS) Anger: 8-item scale which assesses anger. Scores range from 8 to 40, with higher scores indicating greater anger. Perceived Stress Scale: 10-item measure of general distress and perceived ability to cope. Scores range from 0 to 40, higher scores indicate greater stress.

Time frame: Baseline; 12 weeks

ArmMeasureGroupValue (LEAST_SQUARES_MEAN)
SMT-enhanced Cardiac RehabilitationChange From Baseline to 12 Weeks in Individual Scaled ScoresPerceived Stress Score-4.2 units on a scale
SMT-enhanced Cardiac RehabilitationChange From Baseline to 12 Weeks in Individual Scaled ScoresBeck Depression Inventory-II-3.5 units on a scale
SMT-enhanced Cardiac RehabilitationChange From Baseline to 12 Weeks in Individual Scaled ScoresSpielberger Anxiety Inventory-State-5.6 units on a scale
SMT-enhanced Cardiac RehabilitationChange From Baseline to 12 Weeks in Individual Scaled ScoresGeneral Health Questionnaire-4.8 units on a scale
SMT-enhanced Cardiac RehabilitationChange From Baseline to 12 Weeks in Individual Scaled ScoresPROMIS Anger Questionnaire-2.0 units on a scale
Standard Cardiac RehabilitationChange From Baseline to 12 Weeks in Individual Scaled ScoresPROMIS Anger Questionnaire-1.0 units on a scale
Standard Cardiac RehabilitationChange From Baseline to 12 Weeks in Individual Scaled ScoresGeneral Health Questionnaire-3.3 units on a scale
Standard Cardiac RehabilitationChange From Baseline to 12 Weeks in Individual Scaled ScoresBeck Depression Inventory-II-2.6 units on a scale
Standard Cardiac RehabilitationChange From Baseline to 12 Weeks in Individual Scaled ScoresPerceived Stress Score-2.6 units on a scale
Standard Cardiac RehabilitationChange From Baseline to 12 Weeks in Individual Scaled ScoresSpielberger Anxiety Inventory-State-2.6 units on a scale
p-value: <0.05ANCOVA
Secondary

Baroreflex Sensitivity

Baroreflex sensitivity was obtained from beat-to-beat heart rate and blood pressure recorded from patients in the supine position with a Nexfin noninvasive blood pressure monitor.

Time frame: At 12 weeks

ArmMeasureValue (LEAST_SQUARES_MEAN)
SMT-enhanced Cardiac RehabilitationBaroreflex Sensitivity0.47 ms/mm Hg
Standard Cardiac RehabilitationBaroreflex Sensitivity0.93 ms/mm Hg
p-value: 0.9995% CI: [-0.78, 1.74]ANCOVA
Secondary

Change in High-sensitivity C-Reactive Protein

High-sensitivity C-reactive protein was quantified by ELISA. Values \>10 mg/L were truncated at 10 to account for acute inflammatory processes that may have skewed the distribution of this blood marker.

Time frame: Baseline; 12 weeks

ArmMeasureValue (LEAST_SQUARES_MEAN)
SMT-enhanced Cardiac RehabilitationChange in High-sensitivity C-Reactive Protein-0.9 mg/L
Standard Cardiac RehabilitationChange in High-sensitivity C-Reactive Protein-0.4 mg/L
p-value: 0.9595% CI: [-0.14, 1.17]ANCOVA
Secondary

Heart Rate Variability During Controlled Breathing (HRV-DB)

Heart rate variability was obtained from beat-to-beat heart rate. Heart rate was assessed from R-R interval changes elicited during a 100-second controlled breathing task.

Time frame: At 12 weeks

ArmMeasureValue (LEAST_SQUARES_MEAN)
SMT-enhanced Cardiac RehabilitationHeart Rate Variability During Controlled Breathing (HRV-DB)13.1 ms
Standard Cardiac RehabilitationHeart Rate Variability During Controlled Breathing (HRV-DB)26.0 ms
p-value: 0.9995% CI: [-0.22, 0.46]ANCOVA
Secondary

Heart Rate Variability During Rest

Heart rate variability was obtained from beat-to-beat heart rate. Heart rate was assessed from R-R interval changes elicited during 5 minutes of normal relaxed breathing

Time frame: At 12 weeks

ArmMeasureGroupValue (LEAST_SQUARES_MEAN)
SMT-enhanced Cardiac RehabilitationHeart Rate Variability During RestLow-frequency0.17 ln (ms^2)
SMT-enhanced Cardiac RehabilitationHeart Rate Variability During RestHigh-frequency0.08 ln (ms^2)
Standard Cardiac RehabilitationHeart Rate Variability During RestLow-frequency0.28 ln (ms^2)
Standard Cardiac RehabilitationHeart Rate Variability During RestHigh-frequency0.22 ln (ms^2)
p-value: 0.9995% CI: [-0.22, 0.46]ANCOVA
p-value: 0.9995% CI: [-0.14, 0.39]ANCOVA
Secondary

Major Adverse Cardiovascular Events (MACE) - All Cause Death, MI, Cardiac Revascularization and Cardiovascular Hospitalization.

Patients documented all medical encounters on an annual basis after enrollment. Medical records were reviewed, and events, categorized on the basis of American College of Cardiology/American Heart Association criteria. The following medical events were included: all-cause mortality, fatal and nonfatal myocardial infarction (MI), coronary or peripheral artery revascularization, stroke/transient ischemic attack, and unstable angina requiring hospitalization.

Time frame: Baseline through Follow-up (median, 3.2 years)

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
SMT-enhanced Cardiac RehabilitationMajor Adverse Cardiovascular Events (MACE) - All Cause Death, MI, Cardiac Revascularization and Cardiovascular Hospitalization.All cause mortality0 Participants
SMT-enhanced Cardiac RehabilitationMajor Adverse Cardiovascular Events (MACE) - All Cause Death, MI, Cardiac Revascularization and Cardiovascular Hospitalization.MI1 Participants
SMT-enhanced Cardiac RehabilitationMajor Adverse Cardiovascular Events (MACE) - All Cause Death, MI, Cardiac Revascularization and Cardiovascular Hospitalization.Stent/CABG9 Participants
SMT-enhanced Cardiac RehabilitationMajor Adverse Cardiovascular Events (MACE) - All Cause Death, MI, Cardiac Revascularization and Cardiovascular Hospitalization.Stroke/TIA1 Participants
SMT-enhanced Cardiac RehabilitationMajor Adverse Cardiovascular Events (MACE) - All Cause Death, MI, Cardiac Revascularization and Cardiovascular Hospitalization.Peripheral Revascularization1 Participants
SMT-enhanced Cardiac RehabilitationMajor Adverse Cardiovascular Events (MACE) - All Cause Death, MI, Cardiac Revascularization and Cardiovascular Hospitalization.Angina Requiring Hospitalization2 Participants
Standard Cardiac RehabilitationMajor Adverse Cardiovascular Events (MACE) - All Cause Death, MI, Cardiac Revascularization and Cardiovascular Hospitalization.Peripheral Revascularization3 Participants
Standard Cardiac RehabilitationMajor Adverse Cardiovascular Events (MACE) - All Cause Death, MI, Cardiac Revascularization and Cardiovascular Hospitalization.All cause mortality2 Participants
Standard Cardiac RehabilitationMajor Adverse Cardiovascular Events (MACE) - All Cause Death, MI, Cardiac Revascularization and Cardiovascular Hospitalization.Stroke/TIA1 Participants
Standard Cardiac RehabilitationMajor Adverse Cardiovascular Events (MACE) - All Cause Death, MI, Cardiac Revascularization and Cardiovascular Hospitalization.MI6 Participants
Standard Cardiac RehabilitationMajor Adverse Cardiovascular Events (MACE) - All Cause Death, MI, Cardiac Revascularization and Cardiovascular Hospitalization.Angina Requiring Hospitalization2 Participants
Standard Cardiac RehabilitationMajor Adverse Cardiovascular Events (MACE) - All Cause Death, MI, Cardiac Revascularization and Cardiovascular Hospitalization.Stent/CABG11 Participants
95% CI: [0.24, 0.91]Log Rank

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026